Feifei Ren1, Yufeng Ma2, Xiaochen Zhu1, Rongjuan Guo1, Jialin Wang1, Lijuan He3. 1. Dongfang Hospital, Beijing University of Traditional Chinese Medicine, Beijing, 100078, China. 2. Third Affiliated Hospital, Beijing University of Traditional Chinese Medicine, Beijing, 100029, China. 3. Dongfang Hospital, Beijing University of Traditional Chinese Medicine, Beijing, 100078, China. Electronic address: ljhebj@126.com.
Abstract
BACKGROUND: Antidepressants (ADs) are the main clinical therapy for depression, but approximately half of users do not get adequate response. The biallelic (5-HTTLPR) and triallelic (5-HTTLPR/rs25531) polymorphisms in SLC6A4 have been frequently investigated, but their associations with ADs response are in controversy. Here, we performed a meta-analysis to assess their modulation effect to ADs response in major depressive disorder (MDD). METHODS: We performed literature search in PubMed, Web of Science and EMBASE before June 2019. Pooled analysis of genetic associations with response and remission, meta-regression and sensitivity analysis were performed, and publication bias was assessed. RESULTS: Literature search yielded 49 eligible studies with 46 and 10 studies for biallelic and triallelic polymorphism, respectively. L allele of 5-HTTLPR was associated with both of response and remission rates. In the Caucasians using SSRIs only, carriers of LL/LS or LL genotype were more likely to be responders compared to SS carriers (LL/LS vs. SS: OR=1.55, 95%CI 1.20-2.00, p=0.001; LL vs. SS: OR=1.97, 95%CI 1.45-2.67, p<0.001). Similar associations were also found with remission rate. However, no effects on response or remission were found in the Asians or mixed/other antidepressant subgroups. Additionally, the 5-HTTLPR/rs25531 triallelic polymorphism may not associate with ADs response. Meta-regression showed that percent of female in participants, year of publication and treatment duration modulated the association in Caucasians. CONCLUSION: 5-HTTLPR, instead of 5-HTTLPR/rs25531 triallelic polymorphism, may exert as a marker for the prediction of response to SSRIs in Caucasians with MDD.
BACKGROUND: Antidepressants (ADs) are the main clinical therapy for depression, but approximately half of users do not get adequate response. The biallelic (5-HTTLPR) and triallelic (5-HTTLPR/rs25531) polymorphisms in SLC6A4 have been frequently investigated, but their associations with ADs response are in controversy. Here, we performed a meta-analysis to assess their modulation effect to ADs response in major depressive disorder (MDD). METHODS: We performed literature search in PubMed, Web of Science and EMBASE before June 2019. Pooled analysis of genetic associations with response and remission, meta-regression and sensitivity analysis were performed, and publication bias was assessed. RESULTS: Literature search yielded 49 eligible studies with 46 and 10 studies for biallelic and triallelic polymorphism, respectively. L allele of 5-HTTLPR was associated with both of response and remission rates. In the Caucasians using SSRIs only, carriers of LL/LS or LL genotype were more likely to be responders compared to SS carriers (LL/LS vs. SS: OR=1.55, 95%CI 1.20-2.00, p=0.001; LL vs. SS: OR=1.97, 95%CI 1.45-2.67, p<0.001). Similar associations were also found with remission rate. However, no effects on response or remission were found in the Asians or mixed/other antidepressant subgroups. Additionally, the 5-HTTLPR/rs25531 triallelic polymorphism may not associate with ADs response. Meta-regression showed that percent of female in participants, year of publication and treatment duration modulated the association in Caucasians. CONCLUSION:5-HTTLPR, instead of 5-HTTLPR/rs25531 triallelic polymorphism, may exert as a marker for the prediction of response to SSRIs in Caucasians with MDD.
Authors: Victoria S Marshe; Malgorzata Maciukiewicz; Anne-Christin Hauschild; Farhana Islam; Li Qin; Arun K Tiwari; Etienne Sibille; Daniel M Blumberger; Jordan F Karp; Alastair J Flint; Gustavo Turecki; Raymond W Lam; Roumen V Milev; Benicio N Frey; Susan Rotzinger; Jane A Foster; Sidney H Kennedy; James L Kennedy; Benoit H Mulsant; Charles F Reynolds; Eric J Lenze; Daniel J Müller Journal: Transl Psychiatry Date: 2021-02-15 Impact factor: 6.222
Authors: Céline K Stäuble; Rebecca Meier; Markus L Lampert; Thorsten Mikoteit; Martin Hatzinger; Samuel S Allemann; Kurt E Hersberger; Henriette E Meyer Zu Schwabedissen Journal: Front Psychiatry Date: 2022-07-15 Impact factor: 5.435
Authors: Fahad Aldosary; Sandhaya Norris; Philippe Tremblay; Jonathan S James; James C Ritchie; Pierre Blier Journal: Int J Neuropsychopharmacol Date: 2022-04-19 Impact factor: 5.176